Current Gastroenterology Reports

, Volume 14, Issue 6, pp 473–479 | Cite as

Chronic Proton Pump Inihibitor Therapy and Calcium Metabolism

Stomach and Duodenum (J Pisegna, Section Editor)

Abstract

Proton pump inhibitors (PPIs) have been widely used since their introduction in the late 1980s because they are highly effective for acid-related conditions. However, some recent epidemiological studies have suggested a positive association between PPI therapy and the risk of osteoporotic fractures. The potential mechanisms underlying this association may be related to the physiologic effects of chronic acid suppression on calcium metabolism. First, chronic hypergastrinemia induced by PPI therapy may lead to parathyroid hyperplasia, resulting in increased loss of calcium from the bone. Second, profound gastric acid suppression may reduce the bioavailability of calcium for intestinal absorption. I will review the published evidence regarding these potential links and discuss their clinical implications.

Keywords

Proton pump inhibitors Hypergastrinemia Hyperparathyroidism Calcium absorption Osteoporosis PPIs and calcium metabolism PPI-induced hypergastrinemia Parathyroid glands Bone metabolism Calcium balance 

References

  1. 1.
    Leibson CL, Tosteson AN, Gabriel SE, et al. Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc. 2002;50:1644–50.PubMedCrossRefGoogle Scholar
  2. 2.
    Chrischilles EA, Butler CD, Davis CS, et al. A model of lifetime osteoporosis impact.[erratum appears in Arch Intern Med 1922 Mar;152(3):655]. Arch Intern Med. 1991;151:2026–32.PubMedCrossRefGoogle Scholar
  3. 3.
    Hetzel DJ. Controlled clinical trials of omeprazole in the long-term management of reflux disease. Digestion. 1992;51:35–42.PubMedCrossRefGoogle Scholar
  4. 4.
    DeVault KR, Castell DO, American College of G, et al. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100:190–200.PubMedCrossRefGoogle Scholar
  5. 5.
    Bashford JN, Norwood J, Chapman SR. Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database [see comments]. BMJ. 1998;317:452–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Martin RM, Lim AG, Kerry SM, et al. Trends in prescribing H2-receptor antagonists and proton pump inhibitors in primary care. Aliment Pharmacol Ther. 1998;12:797–805.PubMedCrossRefGoogle Scholar
  7. 7.
    Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine h(2) receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79:76–83.PubMedCrossRefGoogle Scholar
  8. 8.
    Yang Y-X, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947–53.PubMedCrossRefGoogle Scholar
  9. 9.
    de Vries F, Cooper A, Logan R, et al. Fracture risk in patients receiving concomitant bisphosphonate and acid-suppressive medication or bisphosphonate alone. Osteoporos Int. 2007;18:S261.CrossRefGoogle Scholar
  10. 10.
    Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures.[see comment]. CMAJ Can Med Assoc J. 2008;179:319–26.CrossRefGoogle Scholar
  11. 11.
    Khalili H, Huang ES, Jacobson BC, et al. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ. 2012;344:e372.PubMedCrossRefGoogle Scholar
  12. 12.
    Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med. 2011;170:765–71.Google Scholar
  13. 13.
    Corley DA, Kubo A, Zhao W, et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010;139:93–101.PubMedCrossRefGoogle Scholar
  14. 14.
    Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008;28:951–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008;83:251–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Pouwels S, Lalmohamed A, Souverein P, et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int. 2011;22:903–10.PubMedCrossRefGoogle Scholar
  17. 17.
    FDA. Drug safety communication: possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. 2010.Google Scholar
  18. 18.
    Jilka RL, Weinstein RS, Bellido T, et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone.[see comment]. J Clin Investig. 1999;104:439–46.PubMedCrossRefGoogle Scholar
  19. 19.
    Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997;350:550–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Stewart AF, Vignery A, Silverglate A, et al. Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. J Clin Endocrinol Metab. 1982;55:219–27.PubMedCrossRefGoogle Scholar
  21. 21.
    Brunner G, Creutzfeldt W. Omeprazole in the long-term management of patients with acid-related diseases resistant to ranitidine. Scand J Gastroenterol - Suppl. 1989;166:101–5. discussion 11-3.PubMedCrossRefGoogle Scholar
  22. 22.
    Brunner G, Creutzfeldt W, Harke U, et al. Therapy with omeprazole in patients with peptic ulcerations resistant to extended high-dose ranitidine treatment. Digestion. 1988;39:80–90.PubMedCrossRefGoogle Scholar
  23. 23.
    Koop H, Klein M, Arnold R. Serum gastrin levels during long-term omeprazole treatment. Aliment Pharmacol Ther. 1990;4:131–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Jansen JB, Klinkenberg-Knol EC, Meuwissen SG, et al. Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology. 1990;99:621–8.PubMedGoogle Scholar
  25. 25.
    Lind T, Cederberg C, Forssell H, et al. Relationship between reduction of gastric acid secretion and plasma gastrin concentration during omeprazole treatment. Scand J Gastroenterol. 1988;23:1259–66.PubMedCrossRefGoogle Scholar
  26. 26.
    Lamberts R, Creutzfeldt W, Struber HG, et al. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis [see comments]. Gastroenterology. 1993;104:1356–70.PubMedGoogle Scholar
  27. 27.
    Koop H, Arnold R. Long-term maintenance treatment of reflux esophagitis with omeprazole. Prospective study in patients with H2-blocker-resistant esophagitis. Dig Dis Sci. 1991;36:552–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Hakanson R, Sundler F. Trophic effects of gastrin. Scand J Gastroenterol - Suppl. 1991;180:130–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Wang TC, Koh TJ, Varro A, et al. Processing and proliferative effects of human progastrin in transgenic mice. J Clin Investig. 1996;98:1918–29.PubMedCrossRefGoogle Scholar
  30. 30.
    Grimelius L, Johansson H, Lundqvist G, et al. The parathyroid glands in experimentally induced hypergastrinemia in the rat. Scand J Gastroenterol. 1977;12:739–44.PubMedCrossRefGoogle Scholar
  31. 31.
    Gagnemo-Persson R, Hakanson R, Sundler F, et al. Growth of the parathyroid glands in omeprazole-treated chickens. Scand J Gastroenterol. 1994;29:493–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Gagnemo-Persson R, Samuelsson A, Hakanson R, et al. Chicken parathyroid hormone gene expression in response to gastrin, omeprazole, ergocalciferol, and restricted food intake. Calcif Tissue Int. 1997;61:210–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Cui GL, Syversen U, Zhao CM, et al. Long-term omeprazole treatment suppresses body weight gain and bone mineralization in young male rats. Scand J Gastroenterol. 2001;36:1011–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Mizunashi K, Furukawa Y, Katano K, et al. Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int. 1993;53:21–5.PubMedCrossRefGoogle Scholar
  35. 35.
    Nordin BE. Calcium and osteoporosis. Nutrition. 1997;13:664–86.PubMedCrossRefGoogle Scholar
  36. 36.
    Ensrud KE, Duong T, Cauley JA, et al. Low fractional calcium absorption increases the risk for hip fracture in women with low calcium intake. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 2000;132:345–53.PubMedGoogle Scholar
  37. 37.
    Nordin BE, O'Loughlin PD, Need AG, et al. Radiocalcium absorption is reduced in postmenopausal women with vertebral and most types of peripheral fractures. Osteoporos Int. 2004;15:27–31.PubMedCrossRefGoogle Scholar
  38. 38.
    Ervin RB, Wang CY, Wright JD, et al. Dietary intake of selected minerals for the United States population: 1999-2000. Advance Data 2004:1-5.Google Scholar
  39. 39.
    Radimer K, Bindewald B, Hughes J, et al. Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol. 2004;160:339–49.PubMedCrossRefGoogle Scholar
  40. 40.
    Champagne ET. Low gastric hydrochloric acid secretion and mineral bioavailability. Adv Exp Med Biol. 1989;249:173–84.PubMedCrossRefGoogle Scholar
  41. 41.
    Sheikh MS, Santa Ana CA, Nicar MJ, et al. Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med. 1987;317:532–6.PubMedCrossRefGoogle Scholar
  42. 42.
    Recker RR. Calcium absorption and achlorhydria. N Engl J Med. 1985;313:70–3.PubMedCrossRefGoogle Scholar
  43. 43.
    Chonan O, Takahashi R, Yasui H, et al. Effect of L-lactic acid on the absorption of calcium in gastrectomized rats. J Nutr Sci Vitaminol. 1998;44:869–75.PubMedCrossRefGoogle Scholar
  44. 44.
    Chonan O, Takahashi R, Yasui H, et al. Effect of L-lactic acid on calcium absorption in rats fed omeprazole. J Nutr Sci Vitaminol. 1998;44:473–81.PubMedCrossRefGoogle Scholar
  45. 45.
    Ivanovich P, Fellows H, Rich C. The absorption of calcium carbonate. Ann Intern Med. 1967;66:917–23.PubMedGoogle Scholar
  46. 46.
    Nilas L, Christiansen C, Christiansen J. Regulation of vitamin D and calcium metabolism after gastrectomy. Gut. 1985;26:252–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Thompson J. The stomach and duodenum: Postoperative complications. Philadelphia: Saunders; 1991.Google Scholar
  48. 48.
    Bo-Linn GW, Davis GR, Buddrus DJ, et al. An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Investig. 1984;73:640–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Heaney RP, Smith KT, Recker RR, et al. Meal effects on calcium absorption. Am J Clin Nutr. 1989;49:372–6.PubMedGoogle Scholar
  50. 50.
    Heller HJ, Greer LG, Haynes SD, et al. Pharmacokinetic and pharmacodynamic comparison of two calcium supplements in postmenopausal women.[erratum appears in J Clin Pharmacol 2001 Jan;41(1):116]. J Clin Pharmacol. 2000;40:1237–44.PubMedGoogle Scholar
  51. 51.
    Graziani G, Como G, Badalamenti S, et al. Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant. 1995;10:1376–80.PubMedGoogle Scholar
  52. 52.
    Graziani G, Badalamenti S, Como G, et al. Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload. Role of gastric acid secretion. Nephron. 2002;91:474–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Hardy P, Sechet A, Hottelart C, et al. Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis. Artificial Organs. 1998;22:569–73.PubMedCrossRefGoogle Scholar
  54. 54.
    O'Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118:778–81.PubMedCrossRefGoogle Scholar
  55. 55.
    Serfaty-Lacrosniere C, Wood RJ, Voytko D, et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr. 1995;14:364–8.PubMedGoogle Scholar
  56. 56.
    Hansen KE, Jones AN, Lindstrom MJ, et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res. 2011;25:2786–95.CrossRefGoogle Scholar
  57. 57.
    Heaney RP. Factors influencing the measurement of bioavailability, taking calcium as a model. J Nutr. 2001;131:1344S–8S.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Division of GastroenterologyThe Perelman School of Medicine at the University of PennsylvaniaPhiladelphiaUSA
  2. 2.Center for Clinical Epidemiology and Biostatistics, and Department of Biostatistics and EpidemiologyThe Perelman School of Medicine at the University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations